These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 16977285)

  • 41. Zoster vaccine to prevent postherpetic neuralgia.
    Sederholm B; Peterson D
    J Pain Palliat Care Pharmacother; 2006; 20(4):41-2. PubMed ID: 17182505
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation.
    Miller G; Schaefer H; Yoder S; Miller R; Winokur P; Kotloff K; Klassen D; Wierzbicki M; Amegashie C; Edwards K
    Transpl Infect Dis; 2018 Jun; 20(3):e12874. PubMed ID: 29512282
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Herpes zoster in old adults].
    Lang PO; Belmin J; Michel JP
    Presse Med; 2009 Apr; 38(4):571-83. PubMed ID: 19028069
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Zoster vaccine live (Oka/Merck).
    Robinson DM; Perry CM
    Drugs Aging; 2006; 23(6):525-31; discussion 532-3. PubMed ID: 16872235
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Zoster vaccine live for the prevention of shingles in the elderly patient.
    Zussman J; Young L
    Clin Interv Aging; 2008; 3(2):241-50. PubMed ID: 18686747
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
    Lecrenier N; Beukelaers P; Colindres R; Curran D; De Kesel C; De Saegher JP; Didierlaurent AM; Ledent EY; Mols JF; Mrkvan T; Normand-Bayle M; Oostvogels L; Da Silva FT; Vassilev V; Vinals C; Brecx A
    Expert Rev Vaccines; 2018 Jul; 17(7):619-634. PubMed ID: 30028651
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection.
    Alexander KE; Tong PL; Macartney K; Beresford R; Sheppeard V; Gupta M
    Vaccine; 2018 Jun; 36(27):3890-3893. PubMed ID: 29807711
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevent shingles with Zostavax.
    Laustsen G; Neilson T
    Nurse Pract; 2007 Jun; 32(6):6-7. PubMed ID: 17557014
    [No Abstract]   [Full Text] [Related]  

  • 49. Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Nov; 60(44):1528. PubMed ID: 22071592
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The safety profile of varicella vaccine: a 10-year review.
    Galea SA; Sweet A; Beninger P; Steinberg SP; Larussa PS; Gershon AA; Sharrar RG
    J Infect Dis; 2008 Mar; 197 Suppl 2():S165-9. PubMed ID: 18419392
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular and therapeutic aspects of varicella-zoster virus infection.
    Quinlivan M; Breuer J
    Expert Rev Mol Med; 2005 Aug; 7(15):1-24. PubMed ID: 16098235
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vaccine-strain varicella zoster virus causing recurrent herpes zoster in an immunocompetent 2-year-old.
    Ota K; Kim V; Lavi S; Ford-Jones EL; Tipples G; Scolnik D; Tellier R
    Pediatr Infect Dis J; 2008 Sep; 27(9):847-8. PubMed ID: 18664930
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A post hoc analysis utilizing the FDA toxicity grading scale to assess injection site adverse events following immunization with the live attenuated Zoster Vaccine (ZVL).
    Popmihajlov Z; Pang L; Brown E; Joshi A; Su SC; Kaplan SS; Willis ED
    Hum Vaccin Immunother; 2018; 14(12):2916-2920. PubMed ID: 30024827
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The burden of herpes zoster and postherpetic neuralgia in the United States.
    Weaver BA
    J Am Osteopath Assoc; 2007 Mar; 107(3 Suppl 1):S2-7. PubMed ID: 17488884
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A shingles vaccine.
    Gorman C
    Time; 2005 Jun; 165(24):67. PubMed ID: 15974024
    [No Abstract]   [Full Text] [Related]  

  • 56. Varicella virus and the herpes zoster vaccine. A review of Zostavax and the new AFIP recommendations.
    Ebede TL; Zippin JH
    J Drugs Dermatol; 2008 Dec; 7(12):1173-6. PubMed ID: 19137773
    [No Abstract]   [Full Text] [Related]  

  • 57. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence.
    Oxman MN
    J Am Osteopath Assoc; 2009 Jun; 109(6 Suppl 2):S13-7. PubMed ID: 19553630
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Herpes zoster: epidemiology, natural history, and common complications.
    Weinberg JM
    J Am Acad Dermatol; 2007 Dec; 57(6 Suppl):S130-5. PubMed ID: 18021864
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Another look at shingles treatment.
    Opstelten W
    J Fam Pract; 2010 Jan; 59(1):13. PubMed ID: 20380078
    [No Abstract]   [Full Text] [Related]  

  • 60. Prevention of herpes zoster and its painful and debilitating complications.
    Johnson R; McElhaney J; Pedalino B; Levin M
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S43-8. PubMed ID: 18162246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.